http://www.reportbuyer.com/rss.htmlIn this section you will find information products, including market research reports, on the following sector: Women's Healthen-gbReportbuyerservice@reportbuyer.comenquiries@redwiredesign.comhttp://www.reportbuyer.com/pharma_healthcare/therapeutic/womens_health/u_s_market_womens_health_devices_2009.htmlIn 2008, the U. S. Market for Women's Health was valued at over $2. 1 billion. Over 50% of this value is accounted for by women's health imaging alone. 6ada18cf5c6d0fd332ceab04b6d85b15Tue, 05 May 2009 12:00:00 GBTherapeutic/Women's Healthhttp://www.reportbuyer.com/pharma_healthcare/therapeutic/womens_health/womens_health_worldwide_prescription_drug_markets_4th_edition.htmlWomen's health encompasses all different areas of medicine and it would be a monumental task to address all of the areas that affect women. This report will concentrate on disorders that affect the female reproductive system and other disorders where there is at least a 70% preponderance of women affected by the disorder. The worldwide prescription drug market for women's health consists of total manufacturers' revenues from the following product categories: Autoimmune diseases Cancer Gynecological and Sexually Transmitted Diseases Hormones Osteoporosis Urinary Disorders Women's Health: Worldwide Prescription Drug Markets, represents the fourth time that Kalorama Information has tackled the women's health pharmaceutical market. 6a42cb91eb6736bd0cdc498bfddc0b09Mon, 02 Feb 2009 12:00:00 GBTherapeutic/Women's Healthhttp://www.reportbuyer.com/pharma_healthcare/therapeutic/womens_health/womens_reproductive_disorders_therapeutics_2008_2018_1.htmlVisiongain predicts that there is great potential for the women's reproductive disorders therapeutics market from present onwards, as this new report Women's Reproductive Disorders Therapeutics, 2008-2018 shows. Oral Contraceptive Market The systemic hormonal contraceptive market is currently a $7bn market, with hormonal oral contraceptives dominating the market for many years. The oral pills are increasingly facing competition from other routes of delivery. c78efb3e6c5f6d6031afd9d0d0c0c4f8Tue, 09 Sep 2008 12:00:00 GBTherapeutic/Women's Healthhttp://www.reportbuyer.com0. c84a914b68fefabce9ed60574ade85dcFri, 01 Aug 2008 12:00:00 GBTherapeutic/Women's Healthhttp://www.reportbuyer.com/pharma_healthcare/therapeutic/womens_health/stakeholder_opinions.html The treatment of menopausal symptoms is a common clinical challenge, with vasomotor symptoms affecting an estimated 75% of women aged over 50 years. Hormone replacement therapy (HRT) has formed the mainstay of treatment for almost 60 years and is highly efficacious. However, concerns surrounding the safety of HRT have led to an increase in demand for non-hormonal alternatives. 9ccad810c1618ffcafdfb388bbf031a1Tue, 17 Jun 2008 12:00:00 GBTherapeutic/Women's Healthhttp://www.reportbuyer.com/pharma_healthcare/therapeutic/womens_health/indian_aesthetic_cosmetic_surgery_industry_primer.htmlCosmetic surgery has been practiced in India for a long time but this branch of plastic surgery gained considerable importance and popularity in the last 10-12 years. There has been a notable surge in the Indian cosmetic or aesthetic surgery during the past five years mainly because of the increasing demand for aesthetic procedures from people in the urban cities of Mumbai, Delhi, Kolkata, Chennai, Bangalore, Pune and Chandigarh. Cosmetic surgeries were associated with celebrities and people of the affluent class at a point of time, but today these surgeries are increasingly being taken by the burgeoning middle class whose demand for them is based on their needs. dce6ddaa415ae85cbbbe29a707871651Thu, 01 May 2008 12:00:00 GBTherapeutic/Women's Healthhttp://www.reportbuyer.com/pharma_healthcare/therapeutic/womens_health/female_sexual_dysfunction.html Female sexual dysfunction (FSD) affects an estimate 84 million women across the seven major pharmaceutical markets and represents a significant opportunity for investment. Despite its high prevalence, FSD is poorly understood and defined. Currently there is just one product approved for the treatment of FSD; P&G's Intrinsa (testosterone) is marketed in Germany, France and the UK. 6cb94a143a5039b16e7172209c50f5a1Mon, 02 Jul 2007 12:00:00 GBTherapeutic/Women's Healthhttp://www.reportbuyer.com/pharma_healthcare/therapeutic/womens_health/womens_health_market_outlook_2011.htmlWith increased pricing pressure from generics, limited differentiation among new medicines and pipeline products and declining sales growth, the women's health market is facing threatening competitive forces, prompting major pharmaceutical players to initiate key strategic changes. 'The Women's Health Market Outlook to 2011' is a new report providing analysis of the current and future market for women's health drugs across all major indications. Forecasts are given based on current marketed portfolio, drivers and resistors of growth and R&D pipelines, enabling you to predict changes in the dynamics of the global women's health market. d50d3bb4fe164a04c5947c5100551cc7Sun, 01 Apr 2007 12:00:00 GBTherapeutic/Women's Healthhttp://www.reportbuyer.com/pharma_healthcare/therapeutic/womens_health/stakeholder_opinions_hormonal_contraceptives.html The hormonal contraceptive market grew by 4. 2% from 2004 to $5. 0 billion in 2005. Market growth was driven in part by the strong uptake of Schering AG's Yasmin and Organon's NuvaRing which fulfill key strategies: additional indications and alternative delivery modes. 762961cde9512372b2f28fc9dc0f1d78Thu, 09 Nov 2006 12:00:00 GBTherapeutic/Women's Health